ArticlePLoS neglected tropical diseases2026
Effectiveness, safety, and implementation outcomes of a decentralization program to deliver antivenoms in the Western Brazilian Amazonia: The SAVING program.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence for Amazonian health: validation is the price of entry.Lancet regional health. Americas · 2026Article
- Ethical considerations in decentralizing antivenom treatment in indigenous territories of the Brazilian Amazonia.PLoS neglected tropical diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundSnakebite envenoming (SBE) is a major cause of morbidity in mortality in low-income and middle-income countries. In Brazil, SBE disproportionately affects Indigenous populations. Limited access to antivenom treatment is a key determinant of poor outcomes in these populations. We evaluated the effectiveness and feasibility of a decentralized model of antivenom delivery in Indigenous primary health settings in the Brazilian Amazon.
methodsAn implementation study was carried out in four Indigenous Health Poles across Amazonas state, Brazil. Effectiveness was assessed using a pre-post design based on national surveillance data, comparing time to antivenom administration, clinical severity, specific clinical manifestations, and case-fatality before and after implementation. Occurrence of early adverse reactions from antivenom treatment was assessed. Qualitative data were collected through semi-structured interviews with Indigenous patients, health-care providers, and health-system managers to assess acceptability, adoption, feasibility, fidelity, and sustainability of the intervention. PRINCIPAL
findingsAmong 125 patients treated after decentralization, the proportion receiving antivenom within 6 hours after bite was significantly higher than under usual care (75.8% vs 40.8%; OR 4·5, 95% CI 2·6-7·9). Proportion of mild envenomations were more frequent after decentralization (50.4% vs 32.7%; OR 2·1, 95% CI 1·2-3·6). Five deaths (4%) were reported in the usual care group and one death (0.8%) was reported in the intervention group (5.3, 95% CI 0.6-45.9). Three (2.4%) patients had mild skin adverse reactions, which were properly managed without need for hospital transfer. A high acceptability was observed among Indigenous users and health providers, combined with good compliance by the providers with the clinical protocol and improved trust in local health services. Health providers and managers at all levels expressed willingness to support sustained antivenom delivery in the study settings and scale up to other Indigenous areas.
conclusionDecentralization improved access to antivenom treatment and reduced poor clinical outcomes. Culturally adapted, decentralized care can be safely implemented in remote settings, with important implications for equitable health system strengthening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.